Therapeutic applications of bone marrow-derived stem cells in liver transplantation for end-stage liver diseases

Today, liver transplantation (LT) is the only established treatment for end-stage liver diseases. The de- velopment of LT, including OLT, cadaveric LT, split LT, living donor LT (LDLT), brings hopes to patients with these diseases. However, increasing donor shortage, rejection and life-long immunosuppression with its side effects are the major limitations of this therapy strategy. Bone marrow-derived stem cells (BMDSCs) are capable of differentiating into hepatocyte-like cells and contribute to liver injury repair. The microenvironment of liver injury caused by rejection, ischemia/reperfusion, loss of liver mass, recurrence of HCV and "small-for-size syndrome" after LT can attract a variety of bone marrow-derived stem cell population to the peripheral circulation and then migration to the injury liver to promote the hepatic function restoration. Additionally, BMDSCs can also take part in the functional regeneration of living donor liver after LDLT. This participation in liver regeneration may be associated to the interac- tion between SDF-1and its receptor CXCR4, involving HGF, IL-8, MMP9, and VEGF/VEGFR-2. BMDSC with its bio-characteristics could maintain the allograft tolerance from different angles and in different ways. In conclusion, BMDSCs transplantation, as a new assistant therapeutic method for LT, will ex- pand the space of LT, and provide more survival opportunities for the patients suffering liver diseases in the future.     

骨髓干细胞的可塑性及其在栓塞性疾病中的应用

栓塞性血管阻塞在急性心肌梗死、脑梗塞、血栓闭塞性脉管炎、糖尿病足等发病过程中起着重要作用。目前临床上针对这些疾病的治疗手段主要有：药物溶栓、血管旁路移植和介入手术等,多年来其治疗方法无实质性进展。上个世纪九十年代人们发现了干细胞新的生物学特性—可塑性,对干细胞可塑性的研究以及相关技术的发展为心脏病、老年痴呆、帕金森等的治疗带来了希望,也为栓塞性疾病的治疗开辟了新途径,有望成为治疗手段之一。     

升巨散对实验性血小板减少症的治疗作用研究

采用水提醇沉法将升巨散制成冲剂,对实验性血小板减少症的治疗,表明升巨散具有升高外周血小板数量之功效,差异显著(P<0.15).相继在出血时问、凝血时间和24h 血块收缩实验中,也间接证实本品有升高外周血小板数量之作用。又在骨髓象检查中,发现升巨散能提高骨髓之巨核细胞及血小板数量,差异显著。本品 LD_(50)及95%可信限为70.88±2.62g/kg。     

肿瘤患者化疗后骨髓抑制的护理探讨

通过对113例化疗后骨髓抑制患者采用保护性隔离，皮肤、口腔、上呼吸道、泌尿道护理及饮食、心理等综合性护理措施的观察，发现113例化疗后骨髓抑制患者，经过综合护理措施仅13例出现感染、发热，2例经抗生素治疗无效，死于感染性休克，其余患者的血象均恢复正常，康复出院。所以本护理措施，对促进化疗后骨髓抑制患者的康复有一定的应用价值。     

骨髓干细胞与急性心肌梗死的血管新生

骨髓干细胞可分化为心肌细胞、血管内皮细胞、平滑肌细胞等，能再生心肌和血管，可用于心肌梗死的治疗。本文就骨髓干细胞在血管新生方面的生物学特性及其对心梗后的血管新生作用作一综述。     

生血康对特发性血小板减少性紫癜患者骨髓巨核细胞的影响

目的：观察生血康治疗特发性血小板减少性紫癜（ITP）患者骨髓巨核细胞的变化．方法：治疗组30例，采用生血康（蒙药制剂）3g，每日3次口服，对照组30例，强的松1mg／（ks．d），每日1次顿服（或每日分3次口服）．两组均以6周为一个疗程，6周后强的松逐减量．并观察骨髓象的变化．结果：治疗组治疗后原、幼巨核和颗粒型巨核细胞明显减少，产板型巨核细胞明显增多，与对照组比较具有显著性差异（P〈0．05）．结论：生血康具有促进骨髓巨核细胞的成熟，使原、幼巨核和颗粒型巨核细胞减少，产板型巨核细胞增多致使升高血小板之功能。     

一例遗传性骨髓衰竭综合征中RTEL1基因新突变的研究

本研究旨在探究端粒酶RTEL1(regulator of telomere length 1)突变导致遗传性骨髓衰竭综合征发生的机制以及RTEL1的生物学功能.本研究基于临床上一例男性儿童先天性角化不良患者展开，通过对患者外周血样本进行外显子测序确定存在RTEL1突变.我们成功构建了过表达野生型RTEL1(RTEL1-WT)以及突变型RTEL1(RTEL1-MUT)的293细胞系.通过细胞计数试剂盒8(cell counting kit-8,CCK-8)探究该突变对细胞增殖的影响，并发现RTEL1-MUT的表达影响细胞的增殖.通过免疫沉淀以及质谱技术寻找到了与RTEL1相互作用的蛋白HSP90,通过western blot对相互作用进行了验证，并发现该突变导致二者的相互作用减少.使用HSP90抑制剂STA-9090处理过表达RTEL1-WT以及RTEL1-MUT的293细胞系，发现HSP90的活性影响RTEL1的稳定性.因此，该患儿的RTEL1突变可能通过影响细胞增殖而导致先天性角化不良的发生，而RTEL1功能的改变可能源于突变影响了与HSP90的相互作用，从而影响了RTEL1的稳定性...     

Biodegradable thermogel as culture matrix of bone marrow mesenchymal stem cells for potential cartilage tissue engineering

Poly（lactide-co-glycolide）-poly（ethylene glycol）-poly（lactide-co-glycolide）（PLGA-PEG-PLGA） triblock copolymer was synthesized through the ring-opening polymerization of LA and GA with PEG as macroinitiator and stannous octoate as catalyst. The amphiphilic copolymer self-assembled into micelles in aqueous solutions, and formed hydrogels as the increase of temperature at relatively high concentrations（〉 15 wt%）. The favorable degradability of the hydrogel was confirmed by in vitro and in vivo degradation experiments. The good cellular and tissular compatibilities of the thermogel were demonstrated. The excellent adhesion and proliferation of bone marrow mesenchymal stem cells endowed PLGA-PEGPLGA thermogelling hydrogel with fascinating prospect for cartilage tissue engineering.     

小鼠骨髓间充质干细胞多潜能性的鉴定

目的:鉴定小鼠骨髓间充质干细胞(MSCs)的多分化潜能的起因.方法:从成年小鼠骨髓股骨、胫骨中分离MSCs,并进行原代培养,分别于0、2、4、6、8、10 d提取总RNA,通过RT-PCR检测多潜能特征基因和相关因子、3个胚层特征基因的mRNA的表达情况,以判断MSCs的特性.结果:小鼠MSCs中表达多能性标记基因Oc...